[go: up one dir, main page]

MA30018B1 - Derives de 1-orthofluorophenyl substitues 1, 2, 5-thiazolidinedione utilises comme inhibiteurs de la ptp-ase - Google Patents

Derives de 1-orthofluorophenyl substitues 1, 2, 5-thiazolidinedione utilises comme inhibiteurs de la ptp-ase

Info

Publication number
MA30018B1
MA30018B1 MA30986A MA30986A MA30018B1 MA 30018 B1 MA30018 B1 MA 30018B1 MA 30986 A MA30986 A MA 30986A MA 30986 A MA30986 A MA 30986A MA 30018 B1 MA30018 B1 MA 30018B1
Authority
MA
Morocco
Prior art keywords
compounds
diseases
inhibitors
ptpases
formula
Prior art date
Application number
MA30986A
Other languages
English (en)
Inventor
David Barnes
Gary Mark Coppola
Travis Stams
Sidney Wolf Topiol
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37903424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30018(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30018B1 publication Critical patent/MA30018B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)

Abstract

Les composés de formule : sont des inhibiteurs des protéine-tyrosine-phosphatases (PTPases) et peuvent ainsi être utilisés pour le traitement d'affections induites par l'activité des PTPases. Les composés de la présente invention peuvent également être utilisés comme inhibiteurs d'autres enzymes caractérisées par une région de liaison à la phosphotyrosine, comme le domaine SH2. Par conséquent, les composés de formule (I) peuvent être utilisés pour la prévention et/ou le traitement d'une résistance à l'insuline associée à l'obésité, d'une intolérance au glucose, du diabète sucré, de l'hypertension et de maladies ischémiques des gros et des petits vaisseaux sanguins, d'affections qui accompagnent le diabète de type 2, y compris une hyperlipidémie, une hypertriglycéridémie, l'athérosclérose, une resténose vasculaire, le syndrome du côlon irritable, la pancréatite, des tumeurs et carcinomes à cellules adipeuses, tels que le liposarcome, une dyslipidémie et d'autres affections dans lesquelles est indiquée une résistance à l'insuline. De plus, les composés de la présente invention peuvent être utilisés pour traiter et/ou prévenir un cancer, l'ostéoporose, des maladies neurodégénératives et infectieuses, et des maladies impliquant une inflammation et le système immunitaire.
MA30986A 2005-12-08 2008-06-02 Derives de 1-orthofluorophenyl substitues 1, 2, 5-thiazolidinedione utilises comme inhibiteurs de la ptp-ase MA30018B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74849205P 2005-12-08 2005-12-08

Publications (1)

Publication Number Publication Date
MA30018B1 true MA30018B1 (fr) 2008-12-01

Family

ID=37903424

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30986A MA30018B1 (fr) 2005-12-08 2008-06-02 Derives de 1-orthofluorophenyl substitues 1, 2, 5-thiazolidinedione utilises comme inhibiteurs de la ptp-ase

Country Status (23)

Country Link
US (1) US8252820B2 (fr)
EP (1) EP1963293A1 (fr)
JP (1) JP2009518419A (fr)
KR (1) KR20080075218A (fr)
CN (1) CN101336235A (fr)
AR (1) AR058285A1 (fr)
AU (1) AU2006321902B2 (fr)
BR (1) BRPI0619567A2 (fr)
CA (1) CA2631007A1 (fr)
CR (1) CR10047A (fr)
EC (1) ECSP088509A (fr)
GT (1) GT200800093A (fr)
IL (1) IL191711A0 (fr)
MA (1) MA30018B1 (fr)
NO (1) NO20083030L (fr)
NZ (1) NZ568663A (fr)
PE (2) PE20071094A1 (fr)
RU (1) RU2008127262A (fr)
TN (1) TNSN08248A1 (fr)
TW (1) TW200800928A (fr)
UA (1) UA94921C2 (fr)
WO (1) WO2007067612A1 (fr)
ZA (1) ZA200804489B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629819A1 (fr) * 2005-12-08 2007-06-14 Novartis Ag Derives de 1,2,5-thiazolidine utiles dans le traitement d'etats induits par les proteine tyrosine phosphatases (ptpase)
BRPI0619547A2 (pt) * 2005-12-08 2011-10-04 Novartis Ag 1,1,3-trioxo-1,2,5-tiadiazolidinas, composição farmacêutica e uso das mesmas
WO2007115058A2 (fr) * 2006-03-31 2007-10-11 Novartis Ag Composés organiques
DE102007015169A1 (de) * 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2609065B1 (fr) * 2010-08-26 2015-07-08 Albemarle Corporation Procédés de production de 1-bromo-2 (cyclopropyl méthoxy)-5 fluoro-4- méthoxybenzène
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
EP2683705B1 (fr) 2011-03-08 2015-04-22 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2017078499A2 (fr) * 2015-11-06 2017-05-11 경북대학교 산학협력단 Composition pour la prévention ou le traitement d'une maladie neuroinflammatoire, contenant un inhibiteur de la protéine tyrosine phosphatase
CA3104507A1 (fr) 2018-06-21 2019-12-26 Calico Life Sciences Llc Inhibiteurs de proteine tyrosine phosphatase et leurs procedes d'utilisation
CA3110035A1 (fr) 2018-09-18 2020-03-26 Basf Se Composes de diaminotriazine
WO2020186199A1 (fr) 2019-03-14 2020-09-17 Calico Life Sciences Llc Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
AU2020407648A1 (en) * 2019-12-18 2022-06-30 Abbvie Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2021127586A1 (fr) * 2019-12-20 2021-06-24 Calico Life Sciences Llc Agents de dégradation de protéine tyrosine phosphatase et leurs méthodes d'utilisation
MX2023002953A (es) * 2020-09-11 2023-06-01 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y métodos para su uso.
KR20230137954A (ko) 2021-01-27 2023-10-05 바스프 에스이 디아미노트리아진 화합물
CN117279913A (zh) * 2021-03-11 2023-12-22 金橘生物科技公司 杂环化合物及其用途
EP4430038A1 (fr) * 2021-11-11 2024-09-18 Calico Life Sciences LLC Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
EP4430039A1 (fr) * 2021-11-11 2024-09-18 Calico Life Sciences LLC Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
KR20240144965A (ko) * 2022-01-31 2024-10-04 브리스톨-마이어스 스큅 컴퍼니 단백질 티로신 포스파타제의 억제제, 조성물 및 사용 방법
CN119137117A (zh) * 2022-02-02 2024-12-13 耐瑞欧医疗公司 蛋白酪氨酸磷酸酶抑制剂及其用途
EP4472957A1 (fr) * 2022-02-02 2024-12-11 Nerio Therapeutics, Inc. Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations
EP4472958A1 (fr) * 2022-02-02 2024-12-11 Nerio Therapeutics, Inc. Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations
WO2024059041A1 (fr) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. N-hétérocycles benzo-fusionnés et leurs utilisations
WO2024067802A1 (fr) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 Inhibiteur de protéine tyrosine phosphatase, son procédé de préparation et son utilisation pharmaceutique
WO2024102794A1 (fr) * 2022-11-09 2024-05-16 Bristol-Myers Squibb Company Inhibiteurs de protéine tyrosine phosphatase, compositions et procédés d'utilisation
US20240228476A1 (en) * 2022-12-21 2024-07-11 Bristol-Myers Squibb Company Inhibitors of protein tyrosine phosphatase, compositions, and methods of use
WO2024141015A1 (fr) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations
CN118852335A (zh) * 2023-04-28 2024-10-29 中科中山药物创新研究院 噻二唑烷酮衍生物及其制备方法和应用
WO2025011570A1 (fr) * 2023-07-11 2025-01-16 深圳众格生物科技有限公司 Inhibiteur de protéine tyrosine phosphatase, composition le comprenant et son utilisation médicale
WO2025016909A1 (fr) * 2023-07-14 2025-01-23 Katholieke Universiteit Leuven Nouveaux composés pour traiter le cancer et des maladies métaboliques
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254342A1 (en) * 2001-03-23 2002-10-08 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
BR0308974A (pt) 2002-04-03 2005-02-15 Novartis Ag Derivados de 1,1-dioxo-1,2,5-tiazolidina-3-ona 5-substituìdos como inibidores de ptpase 1b
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
GB0227813D0 (en) * 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
ATE432074T1 (de) * 2002-12-30 2009-06-15 Vertex Pharma Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7141596B2 (en) * 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
BRPI0619547A2 (pt) 2005-12-08 2011-10-04 Novartis Ag 1,1,3-trioxo-1,2,5-tiadiazolidinas, composição farmacêutica e uso das mesmas
CA2629819A1 (fr) 2005-12-08 2007-06-14 Novartis Ag Derives de 1,2,5-thiazolidine utiles dans le traitement d'etats induits par les proteine tyrosine phosphatases (ptpase)
WO2007115058A2 (fr) 2006-03-31 2007-10-11 Novartis Ag Composés organiques

Also Published As

Publication number Publication date
PE20100470A1 (es) 2010-07-13
PE20071094A1 (es) 2008-01-07
NZ568663A (en) 2011-07-29
UA94921C2 (en) 2011-06-25
JP2009518419A (ja) 2009-05-07
US8252820B2 (en) 2012-08-28
RU2008127262A (ru) 2010-01-20
ZA200804489B (en) 2009-08-26
WO2007067612A1 (fr) 2007-06-14
AU2006321902B2 (en) 2011-11-10
TNSN08248A1 (en) 2009-10-30
GT200800093A (es) 2010-07-09
IL191711A0 (en) 2008-12-29
ECSP088509A (es) 2008-07-30
AR058285A1 (es) 2008-01-30
BRPI0619567A2 (pt) 2011-10-04
US20100035942A1 (en) 2010-02-11
KR20080075218A (ko) 2008-08-14
TW200800928A (en) 2008-01-01
CR10047A (es) 2008-10-16
NO20083030L (no) 2008-08-28
CA2631007A1 (fr) 2007-06-14
EP1963293A1 (fr) 2008-09-03
CN101336235A (zh) 2008-12-31
AU2006321902A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
MA30018B1 (fr) Derives de 1-orthofluorophenyl substitues 1, 2, 5-thiazolidinedione utilises comme inhibiteurs de la ptp-ase
MA30202B1 (fr) Composes organiques
TNSN08247A1 (en) 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
EP1921917A4 (fr) Aminopiperidines fusionnees utilisees comme inhibiteurs de dipeptidyl-peptidase-iv pour le traitement ou la prevention du diabete
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
Seno et al. Pyrrolidine inhibitors of human cytosolic phospholipase A2
WO2007115058A3 (fr) Composés organiques
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA32887B1 (fr) Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
Jacobsen et al. Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors
MA27548A1 (fr) Inhibiteurs heterocycliques beta-amines de la dipeptidyl peptidase pour le traitement ou la prevention du diabete.
MA30782B1 (fr) Amides substitues, procede de production et d'utilisation desdits amides
WO2007070434A3 (fr) Amino-piperidines fusionnees en tant qu'inhibiteurs de la dipeptidyl peptidase-4 pour le traitement ou la prevention du diabete
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
MA35874B1 (fr) Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
Dreyton et al. Mechanistic studies of protein arginine deiminase 2: evidence for a substrate-assisted mechanism
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE463492T1 (de) Kondensierte indole als dipeptidyl-peptidase- hemmer zur behandlung oder prävention von diabetes
MA30975B1 (fr) Formulation parenterale d'anticorps anti-peptide abeta
MA30427B1 (fr) Derives bicycliques utilises comme inhibiteurs de cetp
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
BR0308974A (pt) Derivados de 1,1-dioxo-1,2,5-tiazolidina-3-ona 5-substituìdos como inibidores de ptpase 1b
DE602005024004D1 (de) Als beta-sekretase (bace)-hemmer nützliche 2-amino-chinazolinderivate